news

01.31
/
2024
Product News | Molecular Glue vs PROTAC: Which is Better in Drug Design? Jan.31.2024

Product News | Molecular Glue vs PROTAC: Which is Better in Drug Design?

Targeted Protein Degradation (TPD) mainly involves the degradation of target proteins through the ubiquitin-proteasome and lysosome systems. There are nearly ten different technological routes within TPD, among which molecular glue and PROTAC are the fastest growing ones.

MORE++
09.27
/
2023
Product News | ACS Fall 2023 Debuts Heavyweight R&D Results  (3/3) Sep.27.2023

Product News | ACS Fall 2023 Debuts Heavyweight R&D Results (3/3)

The most eye-catching event for medicinal chemists in August was the American Chemical Society (ACS) 2023 Annual Meeting in autumn, during which the latest research results announced by pharmaceutical manufacturers touched every nerve of medicinal chemistr

MORE++
09.27
/
2023
Product News | ACS Fall 2023 Debuts Heavyweight R&D Results  (2/3) Sep.27.2023

Product News | ACS Fall 2023 Debuts Heavyweight R&D Results (2/3)

Last week's American Chemical Society (ACS) 2023 Annual Autumn Meeting in San Francisco, USA, was a great source of inspiration for the innovative drug industry.

MORE++
09.08
/
2023
Product News | ACS Fall 2023 Big Pharma R&D Update (1/3) Sep.08.2023

Product News | ACS Fall 2023 Big Pharma R&D Update (1/3)

The American Chemical Society's (ACS) 2023 Annual Meeting was held in San Francisco, USA, from 13 to 17 August, with the theme of Harnessing the Power of Data.

MORE++
07.03
/
2023
Product News | Lipidation of Semaglutide and Telopeptide Facilitates Oral Administration of Peptide Drugs Jul.03.2023

Product News | Lipidation of Semaglutide and Telopeptide Facilitates Oral Administration of Peptide Drugs

Despite its natural advantages in terms of safety and selectivity, the peptide's Achilles' heel (originally the heel of Achilles, which became his only weakness as it was the only part of his body not immersed in the waters of the River Styx).

MORE++
05.05
/
2023
Product News | Leader in RNAi Therapeutics: Alnylam Pharmaceuticals May.05.2023

Product News | Leader in RNAi Therapeutics: Alnylam Pharmaceuticals

Once a Nobel Prize winner, Alnylam was once rejected by pharmaceutical companies and investors because of safety concerns. At this moment, Alnylam's lipid nanoparticle delivery system (LNP) has successfully brought RNA interference therapy from the clinic

MORE++
04.23
/
2023
Product News | Small Nucleic Acid Drugs (I): A Miracle Drug that Precisely Regulates Gene Expression Apr.23.2023

Product News | Small Nucleic Acid Drugs (I): A Miracle Drug that Precisely Regulates Gene Expression

In the last two years, after small molecules and antibody drugs, small nucleic acid drugs have also gained attention.

MORE++
04.19
/
2023
Company Events | The 88th API China and the 26th CHINA-PHARM Came to Successful Close Apr.19.2023

Company Events | The 88th API China and the 26th CHINA-PHARM Came to Successful Close

The parent company participated in the 88th China International Pharmaceutical API/ Intermediate/ Packaging/ Equipment Fair (API China) and the 26th China International Pharmaceutical (Industry) Exhibition & Technical Exchange Conference (CHINA-PHARM).

MORE++
04.18
/
2023
Company Events | The SAPA-China Annual Conference Drew to a Successful End Apr.18.2023

Company Events | The SAPA-China Annual Conference Drew to a Successful End

The parent company participated in the SAPA-China Annual Conference.

MORE++
04.18
/
2023
Product News | Delayed Launch of Potentially over $1 Billion Heavyweight Drug Apr.18.2023

Product News | Delayed Launch of Potentially over $1 Billion Heavyweight Drug

On February 20, 2023, Astellas ("Astellas") announced that the FDA notified a three-month extension of the PDUFA target date for fezolinetant to May 22, 2023, to allow additional time to complete the review.

MORE++
04.07
/
2023
Product News | Eli Lilly: 20th Century Insulin Specialist, 21st Century Glp-1 Supplier Apr.07.2023

Product News | Eli Lilly: 20th Century Insulin Specialist, 21st Century Glp-1 Supplier

Eli Lilly and Company, which seems to be losing the battle for the insulin market - facing the squeeze from Sanofi and Novo Nordisk - has seen its insulin market share slip from 38% in 2000 to 13.14% currently.

MORE++
03.17
/
2023
Company Events | The 12th Annual ChemPharma International Summit-Asia CIS-Asia 2023 was Successfully Held Mar.17.2023

Company Events | The 12th Annual ChemPharma International Summit-Asia CIS-Asia 2023 was Successfully Held

The parent company participated in the12th Annual ChemPharma International Summit-Asia CIS-Asia 2023.

MORE++
03.16
/
2023
Product News | E3 Ubiquitin Ligase Ligands in PROTACs Technology Mar.16.2023

Product News | E3 Ubiquitin Ligase Ligands in PROTACs Technology

The Ubiquitin-proteasome system (UPS) is an important pathway for selective protein degradation.

MORE++
03.08
/
2023
Product News | Panoramic Layout of ADC Drug Toxins and Linkers Mar.08.2023

Product News | Panoramic Layout of ADC Drug Toxins and Linkers

Antibody-drug conjugates (ADCs) consist of monoclonal antibodies (Antibody) targeting tumor-specific or tumor-associated antigens coupled with different numbers of small molecule toxins (Payload) through a linker, combining the high targeting ability of monoclonal antibodies and the high activity of cytotoxins in tumor tissues. It has the dual advantages of high targeting of monoclonal antibodies and high activity of cytotoxic agents in tumor tissues, and has better efficacy than traditional antibody-based oncology drugs.

MORE++
02.27
/
2023
Product News | Selective TYK2 Inhibition: A Story of Vision and Perseverance Feb.27.2023

Product News | Selective TYK2 Inhibition: A Story of Vision and Perseverance

We sat down with some of the original team members from Schrödinger and Nimbus Therapeutics who led the tyrosine kinase 2 (TYK2) inhibitor program that resulted in NDI-034858, an oral, selective allosteric inhibitor being evaluated for the treatment of multiple autoimmune diseases following successful recent Phase 2b results in psoriasis. On December 24, 2022, Takeda entered into an agreement to acquire Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus Therapeutics, and it’s TK2 inhibitor, NDI-034858, in a $6 billion deal, with $4 billion up front. Here they discuss the challenges they faced and how these were overcome to successfully develop a potential best-in-class medicine – because they had the right vision and mindset to do things very differently.

MORE++
02.14
/
2023
Product News | Discovery Moments: TYK2 Pseudokinase Inhibitor Feb.14.2023

Product News | Discovery Moments: TYK2 Pseudokinase Inhibitor

In this blog, I tell an important part of the scientific adventure story that led to the discovery a novel medicine called deucravacitinib (Sotyktu™). [Disclaimer: I am a full-time employee at Bristol Myers Squibb.

MORE++
02.04
/
2023
Product News | FDA Approved Drugs for Cancer Treatment Feb.04.2023

Product News | FDA Approved Drugs for Cancer Treatment

Cancer cells grow and divide out of control, and spread into surrounding tissues, causing genetic changes. Tobacco use, age and family history, human papillomavirus (HPV), overweight and obesity, and alcohol consumption are found be risk factors for cancer

MORE++
01.31
/
2023
Product News | FDA Approved Drugs for HIV-1 Infection Jan.31.2023

Product News | FDA Approved Drugs for HIV-1 Infection

Human immunodeficiency virus 1 (HIV) is a virus that attacks the immune system by destroying CD4+ T cells (a type of white blood cell that fights infection).

MORE++
01.17
/
2023
Product News | Chemistry of Aziridine Jan.17.2023

Product News | Chemistry of Aziridine

Aziridine derivatives are aza-analogs of epoxides. The aziridine functionality is a valuable intermediate in synthetic organic and medicinal chemistry.

MORE++
01.04
/
2023
Product News | Morpholine in Drug Design Jan.04.2023

Product News | Morpholine in Drug Design

Morpholine is among versatile and efficient synthetic building blocks in medicinal chemistry and pharmacological activities.

MORE++